MannKind Corporation (MNKD) presented its outlook for 2026 at the H.C. Wainwright Global Investment Conference, emphasizing three key catalysts: the pediatric approval of Afrezza, the acquisition of scPharmaceuticals, and the advancement of MNKD-201 in pulmonary fibrosis. The company, with a market capitalization of $1.16 billion, reported trailing twelve-month revenue of $393.63 million, marking a 30% increase from the prior year. However, it remains unprofitable, with a loss of $0.16 per share over the last twelve months, though analysts project a modest earnings per share of $0.03 for 2026. The stock has traded at $3.61, down nearly 10% over the past week and roughly 34% year-to-date, though it has gained 35% in the past six months, reflecting recent momentum despite broader market volatility.
The pediatric approval of Afrezza, originally approved in 2014 for adults, expands its market reach to children aged six and older. The launch targets a highly concentrated physician base—roughly 80% of pediatric endocrinologists work in fewer than 1,000 practices across about 50 academic centers—compared to the broader adult market, which includes over 60,000 endocrinologists. A bridge program offering $35 per prescription has facilitated early access, with real-world data showing smooth transitions to paid coverage within two to three prescriptions. Clinical trial participation among target physicians is also high, with half having prior experience with Afrezza.
The acquisition of scPharmaceuticals, completed in 2025, has accelerated the development of FUROSCIX ReadyFlow, an autoinjector formulation of furosemide. Early adoption data indicate physician submission rates for FUROSCIX are several times higher than those for the previous on-body infuser (OBI), driven by both existing prescribers and new clinicians in cardiology and nephrology. While hospital-based integrated delivery networks (IDNs) present a longer sales cycle, operational integration remains the primary barrier, though real-world evidence efforts are expected to clarify acceptance by year-end.
MNKD-201, an inhaled treatment for idiopathic pulmonary fibrosis (IPF), advanced from Phase I-B to Phase II, where it is being tested in a 153-patient trial comparing 2 mg and 4 mg doses to placebo over 12 weeks. Phase I-B data showed no gastrointestinal distress and a favorable cough profile, with over 90% of patients reporting either no cough or mild symptoms that resolved within the first few weeks. The trial is part of a broader partnership with United Therapeutics, which also includes Tyvaso DPI and ralinepag DPI. Data for MNKD-201 are expected in the first half of 2028.
The company’s strategic focus on expanding Afrezza’s pediatric market, integrating scPharmaceuticals’ pipeline, and advancing MNKD-201 positions it to capitalize on emerging opportunities in diabetes and respiratory care, despite ongoing profitability challenges.
